Gemini Therapeutics Picks Orchard’s Jason Meyenburg for CEO

Jason Meyenburg has been appointed CEO of Gemini Therapeutics. He is also joining the Cambridge, MA, company’s board of directors. Meyenburg was most recently chief commercial officer of Orchard Therapeutics (NASDAQ: [[ticker:ORTX]]), a job he left last week. His experience also includes positions at Vtesse Pharmaceuticals, Sucampo Pharmaceuticals, and Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]). In 2017, Gemini raised $42 million in Series A financing to support development of therapies to treat age-related macular degeneration.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.